- Home
- PIII vs LSTA Comparison
PIII vs LSTA Comparison
Compare PIII & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- LSTA
- Stock Information
- Founded
- PIII 2015
- LSTA 1980
- Country
- PIII United States
- LSTA United States
- Employees
- PIII N/A
- LSTA N/A
- Industry
- PIII Medical/Nursing Services
- LSTA Misc Health and Biotechnology Services
- Sector
- PIII Health Care
- LSTA Health Care
- Exchange
- PIII Nasdaq
- LSTA Nasdaq
- Market Cap
- PIII 28.6M
- LSTA 22.3M
- IPO Year
- PIII N/A
- LSTA N/A
- Fundamental
- Price
- PIII $8.38
- LSTA $2.30
- Analyst Decision
- PIII Strong Buy
- LSTA Strong Buy
- Analyst Count
- PIII 3
- LSTA 2
- Target Price
- PIII $17.50
- LSTA $23.50
- AVG Volume (30 Days)
- PIII 7.0K
- LSTA 21.8K
- Earning Date
- PIII 11-11-2025
- LSTA 11-11-2025
- Dividend Yield
- PIII N/A
- LSTA N/A
- EPS Growth
- PIII N/A
- LSTA N/A
- EPS
- PIII N/A
- LSTA N/A
- Revenue
- PIII $1,461,823,000.00
- LSTA $1,070,000.00
- Revenue This Year
- PIII N/A
- LSTA N/A
- Revenue Next Year
- PIII $9.46
- LSTA N/A
- P/E Ratio
- PIII N/A
- LSTA N/A
- Revenue Growth
- PIII 4.20
- LSTA N/A
- 52 Week Low
- PIII $5.80
- LSTA $1.87
- 52 Week High
- PIII $26.99
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- PIII 59.01
- LSTA 47.19
- Support Level
- PIII $8.46
- LSTA $2.11
- Resistance Level
- PIII $8.90
- LSTA $2.33
- Average True Range (ATR)
- PIII 0.32
- LSTA 0.17
- MACD
- PIII -0.02
- LSTA 0.00
- Stochastic Oscillator
- PIII 49.07
- LSTA 42.59
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.